Glaxosmithkline halts RSV trial after safety recommendation
A late-stage study of Glaxosmithkline’s respiratory syncytial virus vaccine in pregnant women has been put on pause, the company informs Reuters.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
British firm Glaxosmithkline (GSK) has paused a clinical study of its vaccine candidate against respiratory syncytial virus (RSV) due to a safety recommendation from an independent committee, as reported by news company Reuters.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian's biggest competitors have a landmark 2022 ahead
For subscribers
Bavarian Nordic on FDA special status: A huge validation
For subscribers
Pfizer begins phase III trial for vaccine against RSV
For subscribers
